Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia

被引：2
|
作者：
Zhang, Tongtong [1 ,2 ]
Zhou, Haixia [1 ,2 ]
Xu, Mingzhu [1 ,2 ]
Qian, Chongsheng [1 ,2 ]
Sun, Aining [1 ,2 ]
Wu, Depei [1 ,2 ]
Xue, Shengli [1 ,2 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou 215000, Peoples R China
[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou 215000, Peoples R China
来源：
ANNALS OF HEMATOLOGY | 2023年 / 102卷 / 04期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1007/s00277-023-05110-y
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：973 / 975
页数：3
相关论文
共 50 条
  • [31] Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results.
    Mato, Anthony R.
    Sharman, Jeff P.
    Biondo, Juliana
    Wu, Mei
    Mun, Yong
    Kim, Su Young
    Humphrey, Kathryn
    Boyer, Michelle
    Zhu, Qian
    Seymour, John F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Ravandi, Farhad
    Plunkett, William
    Gandhi, Varsha
    Faderl, Stefan
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan A.
    Konopleva, Marina
    Brandt, Mark
    Huang, Xuelin
    Jabbour, Elias
    BLOOD, 2011, 118 (21) : 1550 - 1550
  • [33] Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Lavie, David
    Ozcan, Muhit
    Chaudhry, Arvind
    Zhou, Xuan
    Paydar, Ima
    Farooqui, Mohammed Z. H.
    Ghia, Paolo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S353 - S353
  • [34] Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome.
    Garcia-Manero, Guillermo
    Winer, Eric S.
    DeAngelo, Daniel J.
    Tarantolo, Stefano R.
    Sallman, David Andrew
    Dugan, James
    Groepper, Stefanie
    Giagounidis, Aristoteles
    Gotze, Katharina S.
    Metzeler, Klaus
    Li, Chia-Cheng
    Zhou, Li
    Martinez, Elizabeth
    Lane, Maureen E.
    Von Roemeling, Reinhard W.
    Bohme, Matthias
    Kubasch, Anne Sophie
    Verma, Amit K.
    Platzbecker, Uwe
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia
    Parry, Narissa
    Busch, Caroline
    Assmann, Victoria
    Cassels, Jennifer
    Hair, Alan
    Helgason, G. Vignir
    Wheadon, Helen
    Copland, Mhairi
    CELL DEATH DISCOVERY, 2022, 8 (01)
  • [36] BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia
    Narissa Parry
    Caroline Busch
    Victoria Aßmann
    Jennifer Cassels
    Alan Hair
    G. Vignir Helgason
    Helen Wheadon
    Mhairi Copland
    Cell Death Discovery, 8
  • [37] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 159, 2022)
    Jiang, Qian
    Li, Zongru
    Qin, Yazhen
    Li, Weiming
    Xu, Na
    Liu, Bingcheng
    Zhang, Yanli
    Meng, Li
    Zhu, Huanling
    Du, Xin
    Chen, Suning
    Liang, Yang
    Hu, Yu
    Liu, Xiaoli
    Song, Yongping
    Men, Lichuang
    Chen, Zi
    Niu, Qian
    Wang, Hengbang
    Lu, Ming
    Yang, Dajun
    Zhai, Yifan
    Huang, Xiaojun
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [38] OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
    Ravandi, Farhad
    Carraway, Hetty E.
    Taningco, Lilia
    Dilley, Kimberley
    Laille, Eric
    Gong, Jing
    de Menezes, Daniel Lopes
    Wei, Andrew H.
    BLOOD, 2021, 138
  • [39] Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)
    Ghanem, Hady
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Faderl, Stefan
    Dellasala, Sara E.
    O'Brien, Susan M.
    Burger, Jan A.
    Borthakur, Gautam
    Kadia, Tapan M.
    Quintas-Cardama, Alfonso
    Brandt, Mark
    Pierce, Sherry A.
    Garcia-Manero, Guillermo
    Jabbour, Elias J.
    BLOOD, 2012, 120 (21)
  • [40] Venetoclax in Combination With Low-Dose Cytarabine and/or Actinomycin D in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Patients With IDH1 or IDH2 Mutations
    Daukelaite, Guoda
    Vasilevska, Dominika
    Vaitekenaite, Vilmante
    Trociukas, Igoris
    Pileckyte, Regina
    Griskevicius, Laimonas
    Zucenka, Andrius
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S293 - S294
12345